Contrasting Westaim (OTCMKTS:WEDXF) & Sight Sciences (NASDAQ:SGHT)

Westaim (OTCMKTS:WEDXFGet Free Report) and Sight Sciences (NASDAQ:SGHTGet Free Report) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.


This table compares Westaim and Sight Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Westaim 1,323.83% 22.34% 20.94%
Sight Sciences -67.18% -44.45% -32.01%

Earnings & Valuation

This table compares Westaim and Sight Sciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Westaim $8.63 million 44.70 $183.98 million $0.81 3.72
Sight Sciences $81.06 million 4.19 -$55.55 million ($1.12) -6.10

Westaim has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Westaim, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Westaim and Sight Sciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Westaim 0 0 0 0 N/A
Sight Sciences 1 5 1 0 2.00

Sight Sciences has a consensus price target of $4.70, suggesting a potential downside of 31.19%. Given Sight Sciences’ higher possible upside, analysts clearly believe Sight Sciences is more favorable than Westaim.

Institutional and Insider Ownership

55.5% of Sight Sciences shares are owned by institutional investors. 4.2% of Westaim shares are owned by company insiders. Comparatively, 28.9% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Westaim has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.76, indicating that its stock price is 176% more volatile than the S&P 500.


Westaim beats Sight Sciences on 7 of the 13 factors compared between the two stocks.

About Westaim

(Get Free Report)

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.

About Sight Sciences

(Get Free Report)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Receive News & Ratings for Westaim Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Westaim and related companies with's FREE daily email newsletter.